Alessandro Testolin1, Maria Silvia Favretto2, Stefania Cora3, Carlo Cavedon4. 1. 1 Department of Radiation Oncology, Policlinico Abano Terme, Padua, Italy. 2. 2 Department of Radiation Oncology, San Bortolo Hospital, Vicenza, Italy. 3. 3 Department of Medical Physics, San Bortolo Hospital, Vicenza, Italy. 4. 4 Department of Medical Physics, University of Verona, Borgo Trento Hospital, Verona, Italy.
Abstract
OBJECTIVE: To evaluate the tolerance of stereotactic body radiation therapy (SBRT) for the treatment of secondary lung tumours in patients who underwent previous pneumonectomy. METHODS: 12 patients were retrospectively analysed. The median maximum tumour diameter was 2.1 cm (1-4.5 cm). The median planning target volume was 20.7 cm(3) (2.4-101.2 cm(3)). Five patients were treated with a single fraction of 26 Gy and seven patients with fractionated schemes (3 × 10 Gy, 4 × 10 Gy, 4 × 12 Gy). Lung toxicity, correlated with volume (V) of lung receiving >5, >10 and >20 Gy, local control and survival rate were assessed. Median follow-up was 28 months. RESULTS: None of the patients experienced pulmonary toxicity > grade 2 at the median dosimetric lung parameters of V5, V10 and V20 of 23.1% (range 10.7-56.7%), 7.3% (2.2-27.2%) and 2.7% (0.7-10.9%), respectively. No patients required oxygen or had deterioration of the performance status during follow-up if not as a result of clinical progression of disease. The local control probability at 2 years was 64.5%, and the overall survival at 2 years was 80%. CONCLUSION: SBRT appears to be a safe and effective modality for treating patients with a second lung tumour after pneumonectomy. ADVANCES IN KNOWLEDGE: Our results and similar literature results show that when keeping V5, V10 V20 <50%, <20% and <7%, respectively, the risk of significant lung toxicity is acceptable. Our experience also shows that biologically effective dose 10 >100 Gy, necessary for high local control rate, can be reached while complying with the dose constraints for most patients.
OBJECTIVE: To evaluate the tolerance of stereotactic body radiation therapy (SBRT) for the treatment of secondary lung tumours in patients who underwent previous pneumonectomy. METHODS: 12 patients were retrospectively analysed. The median maximum tumour diameter was 2.1 cm (1-4.5 cm). The median planning target volume was 20.7 cm(3) (2.4-101.2 cm(3)). Five patients were treated with a single fraction of 26 Gy and seven patients with fractionated schemes (3 × 10 Gy, 4 × 10 Gy, 4 × 12 Gy). Lung toxicity, correlated with volume (V) of lung receiving >5, >10 and >20 Gy, local control and survival rate were assessed. Median follow-up was 28 months. RESULTS: None of the patients experienced pulmonary toxicity > grade 2 at the median dosimetric lung parameters of V5, V10 and V20 of 23.1% (range 10.7-56.7%), 7.3% (2.2-27.2%) and 2.7% (0.7-10.9%), respectively. No patients required oxygen or had deterioration of the performance status during follow-up if not as a result of clinical progression of disease. The local control probability at 2 years was 64.5%, and the overall survival at 2 years was 80%. CONCLUSION: SBRT appears to be a safe and effective modality for treating patients with a second lung tumour after pneumonectomy. ADVANCES IN KNOWLEDGE: Our results and similar literature results show that when keeping V5, V10 V20 <50%, <20% and <7%, respectively, the risk of significant lung toxicity is acceptable. Our experience also shows that biologically effective dose 10 >100 Gy, necessary for high local control rate, can be reached while complying with the dose constraints for most patients.
Authors: Philippe Giraud; Alma Sylvestre; Sofia Zefkili; Albert Lisbona; Pierre Bonnette; Françoise Le Pimpec Barthes; Edouard Paris; Christian Perigaud; Alexia Savignoni; Marc-André Mahé Journal: Radiother Oncol Date: 2011-08-22 Impact factor: 6.280
Authors: Frank J Lagerwaard; Peter W J Voet; Jan P van Meerbeeck; Sjaak A Burgers; Suresh Senan Journal: Radiother Oncol Date: 2002-01 Impact factor: 6.280
Authors: Angela van Baardwijk; Wolfgang A Tomé; Wouter van Elmpt; Søren M Bentzen; Bart Reymen; Rinus Wanders; Ruud Houben; Michel Ollers; Philippe Lambin; Dirk De Ruysscher Journal: Radiother Oncol Date: 2012-10-12 Impact factor: 6.280
Authors: Frank J Lagerwaard; Cornelis J A Haasbeek; Egbert F Smit; Ben J Slotman; S Senan Journal: Int J Radiat Oncol Biol Phys Date: 2007-12-31 Impact factor: 7.038
Authors: Richard J Battafarano; Seth D Force; Bryan F Meyers; Jennifer Bell; Tracey J Guthrie; Joel D Cooper; G Alexander Patterson Journal: J Thorac Cardiovasc Surg Date: 2004-03 Impact factor: 5.209
Authors: David Rice; Hyung-Woo Kim; Anita Sabichi; Scott Lippman; J Jack Lee; Brendell Williams; Ara Vaporciyan; W Roy Smythe; Stephen Swisher; Garrett Walsh; Joe B Putnam; Waun Ki Hong; Jack Roth Journal: Ann Thorac Surg Date: 2003-10 Impact factor: 4.330
Authors: Andrew J Arifin; Faiez Al-Shafa; Hanbo Chen; R Gabriel Boldt; Andrew Warner; George B Rodrigues; David A Palma; Alexander V Louie Journal: Transl Lung Cancer Res Date: 2020-04
Authors: Davide Zampieri; Giuseppe Marulli; Giovanni Maria Comacchio; Marco Schiavon; Andrea Zuin; Federico Rea Journal: J Thorac Dis Date: 2018-02 Impact factor: 2.895